This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2016 by Hillel Yaffe Medical Center
Information provided by (Responsible Party):
Hillel Yaffe Medical Center Identifier:
First received: May 31, 2012
Last updated: June 1, 2016
Last verified: June 2016
It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedance-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.

Condition Intervention Phase
Heart Failure Other: Usual treatment of patients with developing acute heart failure Device: Lung Impedance-Guided Therapy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • Prevention of acute heart failure development in acute MI patients [ Time Frame: Three years ]

Secondary Outcome Measures:
  • Improvement of clinical outcome in patients with lung impedance-guided treatments [ Time Frame: Three years ]

Estimated Enrollment: 300
Study Start Date: June 2012
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Conventional Treatment Heart Failure
Conventional Treatment
Other: Usual treatment of patients with developing acute heart failure
Experimental: Lung Impedance-Guided Therapy
Lung Impedance-Guided Therapy
Device: Lung Impedance-Guided Therapy
Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure

Exclusion Criteria:

  • Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01616121

Contact: Michael Shochat, MD, PhD 972-50-6246926

Hillel Yaffe Medical Center Recruiting
Hadera, Israel, 38100
Contact: Michael Shochat, MD, PhD         
Principal Investigator: Michael Shochat, MD, PhD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Hillel Yaffe Medical Center Identifier: NCT01616121     History of Changes
Other Study ID Numbers: 0037-12-HYMC
Study First Received: May 31, 2012
Last Updated: June 1, 2016

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases processed this record on September 19, 2017